language flag

English

  • language flag

    English

  • language flag

    German

  • language flag

    Italian

  • language flag

    Spanish

Therakos Logo - Dark
Languages:
Therakos e-learning platform
  1. Home
  2. Therakos Institute
  3. Centres of Excellence
  4. Interactive Workshop on Heart Transplant

Interactive Workshop on Heart Transplant

13 - 14 June 2023

Location

University Medical Center (UKE) and University Heart Center (UHZ), Hamburg, Germany

University Medical Center (UKE) and University Heart Center (UHZ), Hamburg, Germany

More about the Centre

The Goal

The goal of the Heart Interactive Course is to provide the latest scientific and clinical knowledge on
the possibilities of ECP positioning on the transplant journey and foster discussion between peers.

Agenda

Download Agenda PDF

Day 1 - 13 June 2023

18.00 – 18.15
Welcome and workshop objectives - Prof Markus Barten

 

18.15 – 19.45
Immune monitoring, and the role of human leukocyte antigen and non HLAantibodies, in solid organ transplantation - Prof Birgit Sawitzki

 

19.45 – 20.00
Interactive discussion

 

20.00
Dinner with the faculty

Day 2 - 14 June 2023

09.00 – 09.45
Current short- and long-term problems after heart transplantation - Prof Andreas Zuckermann

 

09.45 – 10.00
Coffee break

 

10.00 – 11.30
The potential role of ECP after heart transplantation

    Proposed mechanism of action of ECP - Prof Markus Barten

    ECP positioning in the treatment algorithm - Prof Andreas Zuckermann

 

11.30 – 12.00
Interactive discussion

 

12.00 – 13.00
Lunch

 

13.00 – 14.00
Cross functional approach to monitoring and follow-up of ECP patients – the
Hamburg experience

    Importance of a cross functional approach in patient care - Prof Francis Ayuk

    Monitoring and follow-up of ECP patients - Prof Markus Barten

 

14.00 – 14.15
Coffee break

 

 

14.15 – 15.45
Patient case studies - All

 

15.45 – 16.00
ECP in heart transplantation – a patient perspective - Patient TBC

 

16.00 – 16.15
Final remarks and close - All

 

ECP: Extracorporeal Photopheresis

 

For this course, participants are required to submit one patient case for discussion 15 days in
advance of the session

 

All speakers are subject to contract.
This is a commercial programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals

Hosted by

Prof Markus Barten
Prof Markus Barten

Surgical Director of Heart Failure Clinic, Department of Cardiovascular Surgery, University Heart & Vascular Center Hamburg, Germany

Prof Francis Ayuk
Prof Francis Ayuk

Deputy Director, Clinic for Stem Cell Transplantation, University Medical Center Hamburg, Germany

Brought to you by the Therakos Institute

This is a commercial programme run by Therakos (UK) Ltd, part of Mallinckrodt Pharmaceuticals

Our Centres of Excellence (CoE) Programme is for customers only. If you are interested in attending our CoE courses please contact your Sales Representative.

You are leaving the THERAKOS.EU website.
Therakos does not review or control the content of non-Therakos websites, and this hyperlink does not constitute an endorsement by Therakos of the site’s content. Therakos privacy procedures do not apply to the owners of a non-Therakos website.

Important Safety Information
For the TherakosTM Photopheresis
Procedure

Indications

The THERAKOSTM CELLEXTM Photopheresis System is indicated for the administration of photopheresis. Please refer to the appropriate product labelling for a complete list of warnings and precautions.

Contraindications

THERAKOSTM Photopheresis is contraindicated in:

  • Patients possessing a specific history of a light sensitive disease.
  • Patients who cannot tolerate extracorporeal volume loss or who have white blood cell counts greater than 25,000 / mm3.
  • Patients who have coagulation disorders or who have previously had a splenectomy.

Warnings and Precautions

THERAKOSTM Photopheresis treatments should always be performed in locations where standard medical emergency equipment is available. Volume replacement fluids and/or volume expanders should be readily available throughout the procedure. Safety in children has not been established.

  • Do not expose the device to a magnetic resonance (MR) environment. The device may present a risk of projectile injury, and thermal injury and burns may occur. The device may generate artifacts in the MR image, or may not function properly.
  • Thromboembolic events, including pulmonary embolism and deep vein thrombosis, have been reported in the treatment of Graft versus Host Disease (GvHD). Special attention to adequate anticoagulation is advised when treating patients with GvHD.
  • When prescribing and administering THERAKOSTM Photopheresis for patients receiving concomitant therapy, exercise caution when changing treatment schedules to avoid increased disease activity that may be caused by abrupt withdrawal of previous therapy.

Adverse Events

  • Hypotension may occur during any treatment involving extracorporeal circulation. Closely monitor the patient during the entire treatment for hypotension.
  • Transient pyretic reactions, 37.7–38.9°C (100–102°F), have been observed in some patients within six to eight hours of reinfusion of the photoactivated leukocyte-enriched blood. A temporary increase in erythroderma may accompany the pyretic reaction.
  • Treatment frequency exceeding labelling recommendations may result in anaemia.
  • Venous access carries a small risk of infection and pain.

Please refer to the THERAKOSTM CELLEXTM Photopheresis System Operator Manual for a complete list of warnings and precautions.

IMPORTANT SAFETY INFORMATION FOR METHOXSALEN USED IN CONJUNCTION WITH THERAKOSTM PHOTOPHERESIS

Contraindications

Methoxsalen is contraindicated in:

  • Patients exhibiting idiosyncratic or hypersensitivity reactions to methoxsalen, psoralen compounds, or any of the excipients
  • Patients with co-existing melanoma, basal cell or squamous cell skin carcinoma
  • Patients who are pregnant, and sexually active men and women of childbearing potential unless adequate contraception is used during treatment
  • Patients with aphakia because of the significantly increased risk of retinal damage due to the absence of a lens

Warnings and Precautions

  • Special care should be exercised in treating patients who are receiving concomitant therapy (either topically or systemically) with known photosensitizing agents.
  • Oral administration of methoxsalen followed by cutaneous UVA exposure (PUVA therapy) is carcinogenic.
  • Patients should be told emphatically to wear UVA absorbing, wrap-around sunglasses for twenty-four (24) hours after methoxsalen treatment. They should wear these glasses any time they are exposed to direct or indirect sunlight, whether they are outdoors or exposed through a window.
  • Safety in children has not been established.

Refer to the package insert for methoxsalen sterile solution (20 micrograms / mL) or the oral 8-methoxypsoralen dosage formulation for a list of all warnings and precautions.

Please refer to the THERAKOSTM CELLEXTM Photopheresis System Operator Manual for a complete list of warnings, precautions and adverse events.

This website is not intended for healthcare professionals based in US, France and Canada.

Please verify your status below.

I am a healthcare professional and

I am eligible to access this part of the website

I am not a healthcare professional.

I would like to return to the homepage

This website is not intended for residents
based in the US, France or Canada.

PLEASE CLICK HERE TO ENTER

If you are a French resident, please visit www.therakos.fr

Applications for the 2022 EIA are now closed.
The 2022 ECP Immunomodulation Investigator Award has been awarded to Professor Andrew Fisher, Professor of Respiratory Transplant Medicine at Newcastle University, and Honorary Consultant Respiratory and Transplant Physician at The Newcastle upon Tyne Hospitals NHS Foundation Trust's Institute of Transplantation. The objective of his project is to perform an in depth mechanistic assessment of Extracorporeal Photopheresis (ECP) treatment in patients suffering from Chronic lung Allograft Dysfunction (CLAD).

Full details are available on our press release page.

Copy the link to share with the HCP by clicking on the button below

 
THANK YOU FOR YOUR MESSAGE
We will take care of your request and get in contact with you soon
 
THANK YOU FOR YOUR APPLICATION
We can confirm we have received your submission.
 
AUTHORISATION

The Therakos e-learning platform wants to access the following information:

Your basic public profile
Your public email address

Please click the below button to authorise it

WELCOME TO THERAKOS.EU MY AREA
Forgot your password? Click Here
Not yet registered?
WELCOME TO THERAKOS.EU MY AREA
Forgot your password?